Ngwaahịa

Bromelain (BR) bụ protease cysteine ​​nke nwere mmetụta mgbochi na nzuzo nke eriri afọ na mbufụt.Otú ọ dị, mmetụta ya na motility eriri afọ bụ nke a na-achọpụtabeghị.Ya mere, anyị nyochara mmetụta nke ihe ọkụkụ a na-enweta na eriri afọ na-agafe na ụmụ oke. A na-enyocha nkwekọrịta na vitro site na-akpali akpali nke dịpụrụ adịpụ ileum, na bath bath, na acetylcholine, barium chloride, ma ọ bụ ọkụ eletrik.A tụrụ motility in vivo site n'ịtụle nkesa nke akara fluorescent nke ọnụ na-enye n'akụkụ obere eriri afọ.A na-enyochakwa njem na steeti pathophysiologic nke pro-inflammatory compound croton mmanụ ma ọ bụ onye na-ahụ maka ọrịa diabetogenic streptozotocin.Bromelain gbochiri nkwekọrịta nke ogige spasmogenic dị iche iche na-ebute n'ime mouse ileum nwere ike yiri ya.A na-ebelata ma ọ bụ mebie mmetụta antispasmodic site na proteolytic enzyme inhibitor, gabexate (15 × 10 (-6) mol L (-1) , protease-activated r eceptor-2 (PAR-2) antagonist, N (1) -3. -methylbutyryl-N (4) -6-aminohexanoyl-piperazine (10 (-4) mol L (-1) , phospholipase C (PLC) inhibitor, neomycin (3 × 10 (-3) mol L (-1) ) , na phosphodiesterase 4 (PDE4) inhibitor, rolipram (10 (-6) mol L (-1) ).Na vivo, BR na-amachibido motility na steeti pathophysiologic n'ụzọ PAR-2-antagonist-sensitive. Ihe data anyị na-egosi na BR na-egbochi mmegharị nke eriri afọ - ọkachamma na ọnọdụ pathophysiologic - yana usoro nwere ike ịgụnye akpụkpọ ahụ PAR-2 ​​na PLC na PDE4 dị ka intracellular. akara.Bromelain nwere ike ịbụ ihe na-edu ndú maka mmepe nke ọgwụ ọhụrụ, na-enwe ike normalize motility intestinal na mbufụt na ọrịa shuga.